---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-017651"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T13:18:09.266003+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Contineum Therapeutics appoints Troy Ignelzi to board as Audit Committee Chair

## Summary
- Troy Ignelzi appointed as Class I director and Chair of Audit Committee, effective May 20, 2024.
- Evert Schimmelpennink stepped down from Audit Committee; Class I directors now Ignelzi and Olivia Ware.
- Ignelzi is CFO of Rapport Therapeutics; previously CFO at Karuna Therapeutics, scPharma, Juventas.
- Ignelzi will receive standard non-employee director compensation including an option for 23,150 shares.
- Board determined Ignelzi independent and an audit committee financial expert under SEC/Nasdaq rules.

## SEC filing metadata
- accession: 0001437749-24-017651
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774924017651/0001437749-24-017651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774924017651/cont20240420_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-017651
- JSON: https://secwatch.observer/filing/0001437749-24-017651.json
- Plain text: https://secwatch.observer/filing/0001437749-24-017651.txt

## Key facts
- Executive change
  Troy Ignelzi was appointed as Class I Director and Chair of Audit Committee at Contineum Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director and Chair of Audit Committee
  source text: On May 20, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Troy Ignelzi as a member of its Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855175/000143774924017651/0001437749-24-017651-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.